Evaluation of non-genomic, clinical risk and survival results in endocrine-sensitive, HER2-negative, lymph node negative breast cancer

Abstract

Background and objectivesIn endocrine-sensitive, HER2 negative, node negative breast cancer, the presence of a low genomic risk allows treatment with adjuvant endocrine therapy alone, obtaining excellent survival rates. The justification for this study is to show that excellent survival rates are also obtained by treating with adjuvant hormone therapy alone, based on clinical risk assessment. Patients and methodsA descriptive, observational and retrospective study was performed between 2006 and 2016 with endocrine-sensitive, HER2 negative, node negative breast cancer, greater than 1cm or between 0.6 and 1cm with unfavourable features. Retrospective review of health records. Mortality data of the National Registry of Deaths. ResultsA total of 203 patients were evaluable for survival. One hundred and twenty-three (60.50%) were treated with adjuvant endocrine therapy alone, 77 (37.90%) with chemotherapy and endocrine therapy, one (0.50%) with chemotherapy alone and 2 (1%) were not treated. The overall survival rate at 5 years was 97% (95% confidence interval [CI] 94–100). Distant recurrence-free interval was 94% (95% CI 90–98). In the subgroup of patients treated with endocrine therapy alone, overall survival and distant recurrence-free interval rates at 5 years were 98% (95% CI 95–100) and 97% (95% CI 93–100), respectively. ConclusionsPatients with endocrine-sensitive, HER2-negative, node negative breast cancer treated with endocrine therapy alone according to their clinical risk have similar survival outcomes as those treated with endocrine therapy according to their genomic risk.